# Trastuzumab Rezetecan(SHR-A1811) Combined With Ivonescimab (AK112) in Locally Advanced or Metastatic Non-small Cell Lung Cancer Harboring HER2 Gene Abnormalities

> **NCT07630077** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 30 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Trastuzumab Rezetecan
- **DRUG:** ivonescimab

## Key facts

- **NCT ID:** NCT07630077
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-01
- **Primary completion:** 2027-07-01
- **Final completion:** 2028-07-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07630077

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07630077, "Trastuzumab Rezetecan(SHR-A1811) Combined With Ivonescimab (AK112) in Locally Advanced or Metastatic Non-small Cell Lung Cancer Harboring HER2 Gene Abnormalities". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07630077. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*